pharma · Major Depression Disorder · Major Depression Disorders
Mylan Specialty
Mylan Pharma UK
Mylan Pharma UK is a pharma organization headquartered in CN. Primary therapeutic focus areas include Major Depression Disorder, Major Depression Disorders. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s),
napa, USA HQ
233 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- napa, USA
- Employees
- 233
- Programs
- 4
- Drugs
- 10
- Patents
- 0
MYL-1603N-3001
Phase 3 · small molecule · Major Depression Disorder
MYL-1603N-3001 for Major Depression Disorder is a Phase 3 program (small_molecule) at Mylan Pharma UK with 1 ClinicalTrials.gov record(s).
Internal code MYL-1603N-3001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Mylan Pharma UK
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Major Depression Disorder
- Status
- active
- Trials
- 1